Treatment Information

Back

Rectal Cancer treatment details. Biologic therapy.

Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada.

Survival: monthsCountry:Canada
Toxiciy Grade:3City/State/Province:Ottawa, Ontario
Treatments:Biologic therapyHospital:Ottawa Regional Cancer Centre
Drugs:Journal:Link
Date:Jul 2002

Description:

Patients: This Phase II study involved 37 treated patients with locally advanced or metastatic colorectal cancer. Twenty-eight patients had metastasis to the liver. Nineteen patients were administered one new agent (ISIS 3521) and eighteen patients received another new agent (ISIS 5132).

Treatment: The trial evaluated two biological agents: (a) ISIS 3521, an antisense inhibitor of the protein kinase C alpha; and (b) ISIS 5132, an antisense inhibitor of c-raf kinase.

Toxicity: The toxicity experienced by patients who received ISIS 5132 included: fatigue (grade 1-3), anorexia (grade 1-2), nausea (grade 1-2), vomiting (grade 1), stomatitis (grade 1), diarrhea (grade 1), infection (grade 2), hemoglobin (grade 1-2), platelets (grade 1, 3), creatinine (grade 1), and liver enzymes (grade 1-3).

Results: There were no complete or partial responses.

Support: ISIS pharmaceuticals supported the study.




Back